• The Trump administration is expected to reclassify marijuana from Schedule I to Schedule III as soon as Wednesday, marking a significant shift in federal drug policy.
  • Reclassification would enable more medical research and allow cannabis businesses to deduct ordinary expenses, potentially boosting profitability, but it does not legalize or decriminalize marijuana nationwide.
  • Cannabis stocks have rallied on the news, though benefits depend on regulatory details and IRS guidance, with implementation likely phased over the coming months.

In a move that could reshape the U.S. cannabis landscape, the Trump administration is poised to reclassify marijuana from Schedule I to Schedule III under federal law, according to people familiar with the matter. The change, expected as early as Wednesday, would ease restrictions on medical research and provide tax relief for compliant cannabis businesses, though it stops short of nationwide legalization.

Efforts to restructure federal marijuana policy have hit a snag in the past, but this executive action signals a fast-moving shift. Reclassification to Schedule III would reduce barriers to investment and banking for cannabis firms, primarily by mitigating Section 280E of the tax code, which currently prohibits deductions for ordinary business expenses in the industry. Without this change, many companies would continue to face steep tax burdens, squeezing margins in an already competitive market.

"What institutional investors are really focused on is regulatory stability," said one industry executive, who spoke on condition of anonymity. "This move could improve the perception of the sector and attract more foreign direct investment." Attempts to reach the Department of Justice for comment were not immediately successful, but sources indicate that formal rulemaking will follow, with a timeline stretching into early next year.

Cannabis stocks surged on the news, with sector indices up over 5% in recent trading, as investors anticipate easier deductibility and improved access to capital. However, the exact benefits hinge on the regulatory language and forthcoming IRS guidance. For example, if implemented, companies might see tax savings that boost profitability over time, but the magnitude will depend on how many costs become deductible and how quickly financial institutions re-engage with cannabis clients.

Policy and political context adds complexity to the development. While rescheduling lowers barriers to research and investment, it does not resolve interstate commerce or create a federal legalization framework. Reactions are mixed, with supporters highlighting research and economic benefits, and opponents raising concerns about youth use and public health. In the short term, expect a phased rollout with interagency guidance, while long-term effects could include expanded medical research and ongoing debates about federal legalization.

Related developments to watch include DEA and DOJ rulemaking updates, IRS tax guidance on Section 280E, and state-level regulatory changes. As one analyst noted, "It's a step forward, but the real impact will unfold gradually as the details become clear."